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OBJECTIVES The aim of this study was to analyze whether L-arginine (L-arg.) has comparable or additive
effects to physical exercise regarding endothelium-dependent vasodilation in patients with
chronic heart failure (CHF).
BACKGROUND Endothelial dysfunction in patients with CHF can be corrected by both dietary supplemen-
tation with L-arg. and regular physical exercise.
METHODS Forty patients with severe CHF (left ventricular ejection fraction 19 6 9%) were randomized
to an L-arg. group (8 g/day), a training group (T) with daily handgrip training, L-arg. and
T (L-arg. 1 T) or an inactive control group (C). The mean internal radial artery diameter was
determined at the beginning and after four weeks in response to brachial arterial adminis-
tration of acetylcholine (ACh) (7.5, 15, 30 mg/min) and nitroglycerin (0.2 mg/min) with a
transcutaneous high-resolution 10 MHz A-mode echo tracking system coupled with a
Doppler device. The power of the study to detect clinically significant differences in
endothelium-dependent vasodilation was 96.6%.
RESULTS At the beginning, the mean endothelium-dependent vasodilation in response to ACh,
30 mg/min was 2.54 6 0.09% (p 5 NS between groups). After four weeks, internal radial
artery diameter increased by 8.8 6 0.9% after ACh 30 mg/min in L-arg. (p , 0.001 vs. C),
by 8.6 6 0.9% in T (p , 0.001 vs. C) and by 12.0 6 0.3% in L-arg. 1 T (p , 0.005 vs. C,
L-arg. and T). Endothelium-independent vasodilation as assessed by infusion of nitroglycerin
was similar in all groups at the beginning and at the end of the study.
CONCLUSIONS Dietary supplementation of L-arg. as well as regular physical exercise improved agonist-
mediated, endothelium-dependent vasodilation to a similar extent. Both interventions
together seem to produce additive effects with respect to endothelium-dependent vasodila-
tion. (J Am Coll Cardiol 2000;35:706–13) © 2000 by the American College of Cardiology
Advances in heart failure research have introduced a new
pathophysiological concept of chronic heart failure (CHF)
as a systemic rather than a cardiac disorder involving
hemodynamic, neurohormonal and peripheral derange-
ments. Alterations in skeletal muscle metabolism and im-
paired vasodilation during exercise have been identified as
factors contributing to key symptoms of CHF like exercise
intolerance (1–4).
Endothelial dysfunction with attenuated vasodilation in
response to acetylcholine (ACh) and reduced ischemic
vasodilation during reactive hyperemia have been demon-
strated in patients with CHF (4,5). The effects of ACh are
mediated by nitric oxide (NO), which is synthesized by
endothelial nitric oxide synthase (eNOS) from the terminal
guanidino nitrogen of its amino acid precursor L-arginine
(L-arg.). Although L-arg. is stored in significant amounts in
intracellular depots, oral supplementation of L-arg. has been
shown to increase exercise-induced blood-flow in patients
with CHF (6).
Endothelial shear stress serves as the primary stimulus for
endothelium-mediated vasodilation during exercise and ini-
tiates the release of NO via receptor-independent activation
of endothelial potassium channels (7,8) and increase of
calcium influx (9). The expression of mRNA for endothelial
nitric oxide synthase (eNOS) is upregulated in cultured
endothelial cells exposed to laminar shear stress (10). These
findings are consistent with recent observations in human
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studies that exercise training enhances NO-mediated vaso-
dilation in patients with CHF (11–13).
As L-arg. supplementation increased endothelial sub-
strate availability and exercise training augmented eNOS
expression and activity, we hypothesized that a combination
of physical exercise and L-arg. might be additive with
regard to correcting endothelial dysfunction in CHF.
METHODS
Subjects. In this study male patients #70 years with CHF
were studied. All patients had clinical, radiological and
echocardiographical signs of CHF and a reduced left ven-
tricular ejection fraction #40% as assessed by angiography.
Exclusion criteria were exercise-induced myocardial isch-
emia, significant valvular heart disease, diabetes mellitus,
smoking (.10 cigarettes/day), hypertension (.165 mm Hg
systolic blood pressure), overt atherosclerotic peripheral
vascular disease and hypercholesterolemia ($240 mg/dL;
$6.2 mmol/L).
Study protocol. The study was approved by the ethics
committee of the University of Leipzig and written in-
formed consent was obtained from all patients. All patients
were in a clinically stable condition for at least three months
prior to enrollment. With the exception of the control
group, all patients stayed in the hospital for the duration of
the study (four weeks). At baseline patients were studied in
a fasting state in a quiet temperature and humidity con-
trolled room. All cardiovascular medications were withheld
for .24 h before assessment of endothelium-dependent
vasodilation.
A 20 g arterial catheter was placed in the brachial artery
of the nondominant arm, and the patient rested for 20 min
in supine position. After adjustment of both ultrasound and
Doppler transducer over the radial artery, measurements of
arterial diameter and flow velocity were performed.
Intraarterial infusions. Baseline measurements of arterial
diameter were performed during infusion of 5% glucose at a
constant rate of 1 mL/min for 3 min. Endothelium-
dependent vasodilation was assessed by infusion of increas-
ing doses of ACh: 7.5 mg/min, 15 mg/min and 30 mg/min
were administered at a constant flow rate of 1 mL/min for
5 min at each concentration level.
For determination of flow-dependent vasodilation
(FDD), a blood pressure cuff was inflated to 50 mm Hg
above the systolic blood pressure for 5 min. After deflation
of the cuff, maximal reactive vasodilation was measured
noninvasively. It is known that blood flow in reactive
hyperemia peaks shortly after release of cuff pressure and
shows an exponential decline falling to 50% of maximal flow
as early as after 25 s (14). The maximal flow-dependent
vasodilation, however, occurs after approximately 40 to 60 s
(15). We, therefore, measured radial artery internal diame-
ter in 5 s intervals for 2 min after cuff deflation. The
maximal internal diameter was recorded as a measure of
FDD (11).
Finally, nitroglycerin was given at a rate of 0.2 mg/min, 1
mL/min for 5 min to assess endothelium-independent
vasodilation.
Between the different measurements described above, an
interval of 2 min was allowed to assure the return of
endothelial function to baseline levels.
Randomization. After baseline measurements, patients
were randomized to one of the following four groups: 1)
control, 2) L-arg. supplementation alone, 3) forearm exer-
cise training alone, and 4) L-arg. supplementation plus
forearm exercise training.
1) Control patients received measurements of endothelial
function as described above at the beginning of the study
and after four weeks and continued their sedentary
lifestyle.
2) L-arg. supplementation. Patients received 8 g L-arg. per
day split into three single doses of 3 g, 2 g and 3 g. L-arg.
was administered as capsules containing 0.5 g L-arg.
each, and intake of medication was closely supervised.
3) Forearm exercise training. Handgrip training (T) was
performed at 70% (i.e., 60 N) of the maximal exercise
capacity six times per day using a handgrip ergometer.
Each training session lasted for the time previously
determined in the maximal exercise test.
4) L-arg. plus training combined L-arg. supplementation
and forearm exercise training into a comprehensive
endothelial treatment scheme.
All measurements were repeated after four weeks. Cardiac
medication remained unchanged during the study period.
Pharmacokinetic study. In a pharmacokinetic study in-
volving 12 patients with CHF (all 10 patients of the L-arg.
group and the first two patients of the L-arg. 1 T group),
the pharmacokinetic properties of oral L-arg. were assessed
at the first and the last day of therapy. Patients received oral
L-arg. in gelatin capsules each containing 0.5 g of L-arg. at
a dosage of 3 g at 8:00 AM, 2 g at 2:00 PM and 3 g at 8:00
PM. Between 8:00 AM and 12:00 PM, blood samples were
drawn at 1 h intervals to determine plasma L-arg. levels.
Abbreviations and Acronyms
ACh 5 acetylcholine
c 5 control
CHF 5 chronic heart failure
DCM 5 dilated cardiomyopathy
eNOS 5 endothelial nitric oxide synthase
FDD 5 flow-dependent dilation
L-arg. 5 L-arginine
NO 5 nitric oxide
NOS 5 nitric oxide synthase
RH 5 reactive hyperemia
T 5 training
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Ultrasound measurement of radial artery diameter. A
high-resolution echo-tracking angiometer (NIUS 02, Asu-
lab Research Laboratory, Neuchaˆtel, Switzerland) was used
for noninvasive measurement of mean radial artery diame-
ter. In brief, short ultrasonic pulses of 10 MHz center
frequency are generated at a pulse repetition frequency of
500 Hz. The radio frequency echo line permits accurate
determination of the internal artery diameter over time by
automatic tracking of the anterior and posterior wall (spatial
resolution: 2 mm) (16). During measurement the patient
was in supine position with the arm resting on a special
support to avoid unintentional motions. It has previously
been demonstrated that ultrasound measurement of artery
diameter correlate with plethysmographic data (17).
Doppler measurement of intravascular blood flow veloc-
ity. Intravascular blood flow velocity was continuously de-
termined using a fixed Doppler probe (Doptek 2003, Deltex
France SA, Montpellier, France) with a Doppler frequency
of 8 MHz. Blood flow was calculated as average peak
velocity multiplied by cross sectional area, yielding flow in
mL/min.
Exercise testing. For testing of maximal forearm exercise
capacity, patients performed dynamic handgrip exercise
with the nondominant forearm using a hand ergometer set
at a force of 80 N and a travel of 0.03 m. Contractions were
repeated at a frequency of 20 per min, and the time until the
patient stopped due to fatigue was determined.
Statistics. All variables were calculated as mean 6 standard
error. Both absolute values and percentage changes from
baseline were used for statistical analysis and yielded similar
p values. Both intragroup and intergroup comparisons were
made using the two-way repeated measures analysis of
variance followed by the Tukey post-hoc test (SigmaStat
2.0.3 for Windows, SPSS Inc., Chicago, Illinois). Data
were tested for normal distribution using the Kolmogorov-
Smirnov test and for homogeneity of variances with Lev-
ene’s test. A p value ,0.05 was considered statistically
significant.
In a previous validation of the NIUS-02 high-resolution
echo-tracking angiometer, we determined a standard devi-
ation of 82 mm for measurements of radial artery diameter
changes at 30 mg/min ACh after a local training interven-
tion in patients with CHF (n 5 7, age 55 6 4 years, left
ventricular ejection fraction 15 6 3%). We therefore esti-
mated a standard deviation of 100 mm for the assessment of
endothelium-dependent vasodilation in this study. A differ-
ence in radial artery diameter exceeding two standard
deviations (i.e., 200 mm) was considered to be clinically
relevant. Based on a sample size of n 5 10 for each of the
four treatment groups, the power of the study to detect
clinically significant differences in endothelium-dependent
vasodilation was calculated to be 96.6%.
RESULTS
Patient characteristics. In this study 40 male patients with
CHF were studied. The etiology of heart failure was related
to ischemic heart disease in 16 patients. In the absence of
identifiable causes of ventricular dysfunction, 24 patients
were diagnosed as having dilated cardiomyopathy (DCM).
Baseline characteristics were similar for all variables in the
four groups (Table 1). Medication was not changed during
the study period in any patient. All patients were taking
angiotensin conversion enzyme inhibitors; 39 patients were
on diuretics and 30 on digitalis.
One patient in the control group died from sudden
arrhythmogenic complications of CHF during the study
period, unrelated to participation in the study. Another
control group patient declined to participate in the
follow-up examination, so that complete follow-up was
available for 38 patients only.
Pharmacokinetic study. Oral L-arg. was effective in dou-
bling the normal serum levels of L-arg. Peak plasma levels were
reached about an hour after administration, and the plasma
Table 1. Baseline Characteristics
Control L-Arg. Training L-Arg. 1 Training
n 10 10 10 10
Age (yr) 56 6 3 55 6 2 55 6 4 55 6 2
LVEF (%) 19 6 3 18 6 2 18 6 3 19 6 3
LVEDD (mm) 67 6 2 69 6 1 68 6 3 69 6 3
DCM/ischemic CMP 7/3 6/4 6/4 5/5
NYHA II 1 2 1 2
III 9 8 9 8
HF (beats/min) 86 6 2 86 6 4 87 6 5 84 6 4
RR systolic (mm Hg) 118 6 4 118 6 3 116 6 6 113 6 3
RR diastolic (mm Hg) 74 6 2 73 6 3 76 6 3 73 6 2
Data are mean 6 SEM.
CMP 5 cardiomyopathy; DCM 5 dilated cardiomyopathy; HR 5 heart rate; L-arg. 5 L-arginine; LVEDD 5 left
ventricular end-diastolic diameter; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association; RR 5
arterial blood pressure.
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half-life period ranged between 2 and 3 h (Fig. 1). No adverse
effects with regard to hypotension were observed in the pilot
study. Apart from mild intermittent diarrhea in one patient, no
further side effects were observed in any other patient. No
significant change in bioavailability was observed between the
beginning and the end of the treatment period (Fig. 1).
Vasodilative response to acetylcholine. Baseline measure-
ments. The baseline vasodilative response was not signifi-
cantly different between the groups after administration of
ACh 30 mg/min as determined by radial artery diameter
(Fig. 2) and blood flow (Fig. 3). Baseline vascular diameter
did not change between the beginning and the end of the
study in any patient group.
Control. The response of radial artery diameter to ACh
remained unchanged after four weeks.
L-arg. After four weeks of L-arg. supplementation at
a dose of 8 g/day, the vasodilative response to ACh 30 mg/min
as compared with baseline (glucose 5%) increased signifi-
cantly from 77 6 5 mm to 280 6 33 mm (from 2.2 6
Figure 1. Average plasma concentrations in 12 chronic heart failure patients taking oral L-arginine at a dose of 8 g/day (3 g at 8:00 AM,
2 g at 2:00 PM, 3 g at 8:00 PM). The straight line denotes plasma levels on the first day of therapy; the dotted line after four weeks of
continuous treatment.
Figure 2. Vasodilative effect of 30 mg/min acetylcholine at the
beginning and after four weeks of L-arg. (triangle), handgrip training
alone (circle) and handgrip training plus L-arg. (black rhombus).
The absolute changes in radial artery internal diameter as compared
with infusion of 5% glucose are presented as mean 6 standard error.
*Denotes p , 0.001 vs. control (square) and begin; #denotes p ,
0.001 vs. L-arg. alone and training alone. L-arg. 5 L-arginine.
Figure 3. Effects of 30 mg/min acetylcholine on blood flow at the
beginning and after four weeks of L-arg. (triangle), handgrip
training alone (circle) and handgrip training plus L-arg. (black
rhombus). The absolute changes in blood flow as compared with
infusion of 5% glucose are presented as mean 6 SE. *Denotes p ,
0.001 vs. control (square) and begin; #denotes p , 0.001 vs.
L-arg. alone and training alone. L-arg. 5 L-arginine.
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0.2 to 8.8 6 0.9%, p , 0.001 vs. begin). Similar changes
were observed with respect to blood flow (Fig. 3).
Local exercise training. After four weeks of handgrip
exercise training, ACh 30 mg/min caused an increase of
internal diameter change from 78 6 5 mm to 278 6 32 mm
(from 2.1 6 0.1% to 8.6 6 0.9%, p , 0.001 vs. begin) (Fig.
2 and 4). Blood flow changes are given in Fig. 3.
Combination of L-arg. supplementation and training. In
comparison with both the L-arg. and the training group, the
vasodilative response to ACh 30 mg/min was significantly
enhanced after four weeks of L-arg. plus handgrip exercise
training: from 98 6 8 mm to 409 6 16 mm (from 2.9 6
0.2% to 12.0 6 0.3%, p , 0.001 vs. begin and vs. control,
p , 0.001 vs. L-arg. and training) (Fig. 2 and 4). Acetyl-
choline induced blood flow augmentation increased from
27.3 6 0.1 mL/min to 36.5 6 0.7 mL/min (p , 0.001 vs.
begin, control, L-arg. and training) (Fig. 3).
Vasodilative response during reactive hyperemia. After
5 min of complete limb ischemia, maximal flow-dependent
vasodilation during reactive hyperemia (RH) was measured.
In all intervention groups (L-arg., training and L-arg. plus
training), RH-induced vasodilation was significantly en-
hanced after four weeks of treatment (Fig. 5). Vasodilation
was more pronounced in the L-arg. 1 training group than
in L-arg. or training alone (15.5 6 1.0% vs. 11.3 6 1.2% in
L-arg. [p 5 0.044] and 11.4 6 0.9% in training [p 5
0.037]).
Vasodilative response to nitroglycerin. After administra-
tion of nitroglycerin 0.2 mg/min, no significant differences
between baseline and follow-up measurements were deter-
mined (control: 402 6 23 mm vs. 394 6 23 mm; L-arg.:
469 6 19 mm vs. 492 6 29 mm; training: 474 6 22 mm vs.
474 6 21 mm; L-arg. plus training: 481 6 25 mm vs. 481 6
24 mm).
Exercise capacity. Maximal handgrip work did not change
in the control group (Fig. 6). In the nontraining L-arg.
group, a slight nonsignificant increase of maximal work was
noted (111% from 354 6 67 J to 394 6 69 J, p 5 NS).
More pronounced were the changes in the training groups:
training alone doubled maximal handgrip work from 374 6
82 J to 718 6 194 J (p , 0.001 vs. begin). The addition of
L-arg. supplementation to exercise training further en-
hanced exercise capacity from 355 6 159 J to 926 6 158 J
(p , 0.001 vs. begin and p 5 0.017 vs. control and L-arg.).
However, the difference between the effects of training 1
L-arg. versus training alone with respect to local exercise
capacity did not reach statistical significance.
Figure 4. Dose-response curves for acetylcholine-induced endothelium-dependent vasodilation before (A) and after four weeks (B) of
L-arg. (triangle), handgrip training alone (circle) and handgrip training plus L-arg. (black rhombus) vs. baseline. *Denotes p , 0.01 vs.
control (square); #denotes p , 0.005 vs. L-arg. alone and training alone. L-arg. 5 L-arginine.
Figure 5. Vasodilative effect of reactive hyperemia. The absolute
changes in radial artery internal diameter as compared with
infusion of 5% glucose are presented as mean 6 SE. *denotes p ,
0.02 vs. begin and control (square); #denotes p , 0.05 vs.
L-arginine (triangle) and training (circle); combination of
L-arginine and training (black rhombus).
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DISCUSSION
Endothelial dysfunction has been corrected in patients with
CHF by oral L-arg. supplementation (6) and physical
exercise training (11–13,18). Since both interventions influ-
ence different sections of the L-arg.—NO—pathway, the
question arises whether the combination of oral L-arg. and
exercise training might be superior to separate interventions
alone.
Two major messages emerge from this first prospective
randomized clinical trial comparing the effects on endothe-
lial dysfunction in CHF of L-arg. alone, training alone and
the combination of L-arg. and training: 1) supplemental
oral L-arg. improves endothelium-dependent vasodilation,
most likely by increased endothelial release of NO. Local
exercise training had similar beneficial effects as compared
with exercise training with respect to ACh-mediated vaso-
dilation. 2) The effects of L-arg. supplementation and
exercise training on endothelium-dependent vasodilation
seem to be additive. This result suggests that improved
endothelial function may be a sum effect of increased
substrate availability and shear stress induced upregulation
of eNOS.
It has long been established that CHF is characterized by
peripheral vasoconstriction and abnormal vascular compli-
ance, both of which may be related, in part, to endothelial
dysfunction of peripheral resistance and conduit vessels
(4,19). Indeed, numerous studies have documented a re-
duced endothelium-dependent vasodilation in CHF pa-
tients (4,16). In addition, it has been found that
endothelium-independent relaxation is not different be-
tween CHF patients and healthy controls (20).
In this study a bifactorial treatment approach to correct
endothelial function in CHF was evaluated: supplementa-
tion of L-arg. and exercise training.
Effects of L-arg. supplementation. Oral supplementation
of L-arg. at a dose of 8 g per day leads to a fourfold increase
in endothelium dependent vasodilation in patients with
CHF after four weeks of treatment. This study confirmed
the beneficial effect of L-arg. supplementation on ACh-
mediated vasodilation in patients with CHF (6,20).
In contrast with this result, Chin-Dusting et al. (21)
reported that oral supplementation of L-arg. at a dose of
20 g per day failed to improve endothelial dysfunction in
patients with CHF. Several differences in this study are to
be noted:
1) L-arg. was administered in a water-based syrup solution,
which was stored at the patients’ homes for the study
period of 28 days.
2) No attempt was made to determine the bioavailability of
oral L-arg. in this water-soluble form.
3) The patients studied by Chin-Dusting et al. were in
more advanced stages of heart failure than our patients
with 7/20 in New York Heart Association class IV.
4) The methodological approach for measuring ACh-
induced vasodilation (forearm venous occlusion plethys-
mography) differed from our study.
Mechanisms involved in the effects of L-arg. supplementation.
In pathological states like reperfusion injury, hypercholes-
terolemia, diabetes mellitus and CHF, reduced NO activity
has been described (5,22–25). L-arg. supplementation may
partially restore NO levels in these situations by a variety of
actions:
1) In reperfusion injury, NO is rapidly degraded by oxygen
radicals. L-arg. supplementation corrected endothelium-
dependent vasodilation by competing with molecular
oxygen as a substrate for electron transfer and reduced
superoxide generation.
2) Elevated levels of asymmetrical dimethylarginine have
been observed in hypercholesterolemic rabbits (26).
Asymmetrical dimethylarginine has been proposed as an
endogeneous regulator of nitric oxide synthase (NOS)
activity and may act via a competitive mechanism, which
is reversed by L-arg.
3) In CHF, elevated levels of free oxygen radicals have been
described (27). L-arg. may act as a radical scavenger and
reduce oxygen radicals, thereby increasing NO half-life
(28).
Effects of exercise training. Local training by submaximal
handgrip exercise six times per day was effective in signifi-
cantly improving endothelial function within four weeks;
ACh-induced vasodilation increased fourfold from 2.1 6
0.1% to 8.6 6 0.9% (p , 0.001). Cell culture experiments
have demonstrated that eNOS activity and NO release are
modulated by alterations of blood flow and shear stress
(8–10,29). Shear stress responsive elements have been
identified within the promotor region of the NOS gene
(30).
Animal studies have confirmed that short-term (31) and
Figure 6. Maximal handgrip exercise capacity before and after
intervention. *Denotes p , 0.001 vs. begin; ‡denotes p 5 0.017 vs.
control and L-arg. Control (square); L-arg. (triangle); training
(circle); L-arg. 1 training (black rhombus). L-arg. 5 L-arginine.
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long-term exercise (31–33) increased the mRNA expression
of eNOS. The effectiveness of exercise training to reverse
endothelial dysfunction has also been documented in hu-
mans (11,13,18).
Effects of a combination of L-arg. supplementation and
exercise training. This study is the first prospective ran-
domized clinical trial to demonstrate that the combination
of oral L-arg. supplementation and regular submaximal
exercise training has additive effects as compared with
L-arg. or exercise training alone. Combination treatment
leads to a difference in agonist-mediated endothelium-
dependent vasodilation of 12 6 0.3% as compared with
8.8 6 0.9% in L-arg. and 8.6 6 0.9% in training, respec-
tively. This finding is consistent with the possible mecha-
nisms of actions of both interventions outlined above
because they interfere at different points of the NO-
pathway.
Reactive hyperemia and flow-dependent vasodilation.
Arterial occlusion is the most potent stimulus for vasodila-
tion in the human forearm (19). Similar to the
endothelium-dependent vasodilation in response to acetyl-
choline, ischemic vascular relaxation is also significantly
attenuated in patients with CHF (19,20).
Different mechanisms are involved in reactive hyperemia:
peak flow seems to be mediated primarily by vasodilating
prostaglandins and myogenic factors (34,35). The initial rise
in blood flow exceeds the perfusion required to repay the
metabolic debt and leads to a wash-out of any locally acting
factors. It has, therefore, been argued that prostaglandins
and myogenic factors are of minor importance for the
vasodilation seen about 40 to 60 s after release of the arterial
occlusion (36). As inhibition of eNOS by NG-monomethyl-
L-arginine has no additional effect on peak hyperemia in the
presence of cyclooxygenase inhibitors but further reduces
total excess blood flow (36), NO has been suggested to
mediate the flow-dependent vasodilation in late reactive
hyperemia (35).
As endothelial factors contribute substantially to reactive
hyperemia, we expected significant changes after L-arg.
supplementation or training. Maximal FDD was signifi-
cantly enhanced after both interventions (after L-arg.
174%, p 5 0.001, after training 147%, p 5 0.009). The
combination of L-arg. and training further augmented
FDD: 190%, p 5 0.037 vs. training and p 5 0.044 vs.
L-arg.).
Clinical implications. One of the key symptoms of CHF
is exercise intolerance, accompanied by early muscular
fatigue. It has been shown that exercise intolerance corre-
lates poorly with central hemodynamics (37). Therefore,
therapeutic strategies in CHF focussing on improving
cardiac function may fail to enhance exercise capacity.
Intact endothelial function seems to play an important
role for adequate peripheral perfusion during exercise. In
this study we confirmed that a combination of supplemen-
tation of oral L-arg. and local exercise training seems to
have superior effects on endothelium-dependent vasodila-
tion in patients with CHF as compared with separate
interventions.
Although the feasibility of long-term oral L-arg. supple-
mentation may be debated for practical reasons, our study
underlines the potential benefits of augmenting endothelial
NO production or release in patients with CHF.
In this study endothelial function was assessed in the
trained extremity, suggesting that local exercise leads only to
local effects. In a consecutive trial we are currently challeng-
ing this traditional concept by investigating whether a
similar effect on forearm endothelial function can be
achieved with bicycle ergometer training. Thereby it should
be possible to differentiate between local and systemic effects
of exercise training on the skeletal muscle vasculature in
CHF.
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